Allogeneic HCT in AML Patients

AML patients ≥18 years of age were included in this retrospective study if they were in first morphologic CR or CR with incomplete peripheral blood count recovery (CRi) irrespective of the presence of MRD, underwent allogeneic HCT with NMA or MA conditioning, and received peripheral blood or bone marrow as stem cell source. We included all patients meeting these criteria if they underwent pre-HCT work up from late April 2006, when a refined MFC-based MRD detection method was introduced at our institution and utilized routinely in all patients, until April 2012. Results on the first 136 MA patients have been reported previously.^{8 (link), 9 (link)} We used the 2008 WHO criteria to define AML^{12 (link)} and the refined United Kingdom Medical Research Council (MRC) criteria to assign cytogenetic risk.^{13 (link)} Secondary leukemia was defined as AML following a history of antecedent hematologic disorder (i.e. myelodysplastic syndrome or myeloproliferative neoplasm) or prior treatment with systemic chemotherapy and/or radiotherapy.
Pretransplantation comorbidities were assessed retrospectively using the HCT-specific comorbidity index (HCT-CI).^{14 (link), 15 (link)} Treatment responses were categorized as proposed by the European LeukemiaNet.^{16 (link)} Criteria for diagnosis and grading of acute and chronic GVHD have been reported previously.^{17 (link), 18 (link)} Information on post-transplant outcomes was captured via the Long-Term Follow-Up Program through medical records from our outpatient clinic and local clinics that provided primary care for patients in addition to records obtained on patients on research studies. All patients were treated on Institutional Review Board-approved protocols or standard treatment protocols and gave consent in accordance with the Declaration of Helsinki. Follow-up was current as of October 1, 2013.

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Walter R.B., Gyurkocza B., Storer B.E., Godwin C.D., Pagel J.M., Buckley S.A., Sorror M.L., Wood B.L., Storb R., Appelbaum F.R, & Sandmaier B.M. (2014). Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation. Leukemia, 29(1), 137-144.

Publication 2014

Blood Cell bone marrow Chemotherapy treatment Diagnosis European Hematologic disorder Institutional review board Leukemia Myelodysplastic syndrome Myeloproliferative neoplasm Patients Peripheral blood count Radiotherapy Stem Transplant Treatment protocols

Corresponding Organization : Fred Hutch Cancer Center

Other organizations : University of Washington, University of Washington Medical Center

Top 5 similar protocols

Protocol cited in 6 other protocols

Variable analysis

independent variables

Conditioning regimen (NMA or MA)

dependent variables

Treatment responses
Acute and chronic GVHD
Post-transplant outcomes

control variables

AML patients ≥18 years of age
First morphologic CR or CR with incomplete peripheral blood count recovery (CRi) irrespective of the presence of MRD
Underwent allogeneic HCT with peripheral blood or bone marrow as stem cell source
Underwent pre-HCT work up from late April 2006, when a refined MFC-based MRD detection method was introduced at the institution and utilized routinely in all patients, until April 2012
Used the 2008 WHO criteria to define AML
Used the refined United Kingdom Medical Research Council (MRC) criteria to assign cytogenetic risk
Secondary leukemia was defined as AML following a history of antecedent hematologic disorder or prior treatment with systemic chemotherapy and/or radiotherapy
Pre-transplantation comorbidities were assessed retrospectively using the HCT-specific comorbidity index (HCT-CI)
Treatment responses were categorized as proposed by the European LeukemiaNet
Diagnosis and grading of acute and chronic GVHD have been reported previously

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!